Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system
暂无分享,去创建一个
D. McAuley | C. Taggart | T. Peto | J. Kidney | M. Bailey | H. Guo-Parke | O. Earley | D. Linden | Olivia Earley
[1] A. Jannot,et al. Fibrin monomers evaluation during hospitalization for COVID-19 is a predictive marker of in-hospital mortality , 2023, Frontiers in Cardiovascular Medicine.
[2] L. Esserman,et al. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial , 2023, eClinicalMedicine.
[3] I. Martín-Loeches,et al. Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19 , 2023, Research and Practice in Thrombosis and Haemostasis.
[4] C. Samama,et al. Platelet activation and coronavirus disease 2019 mortality: Insights from coagulopathy, antiplatelet therapy and inflammation , 2023, Archives of Cardiovascular Diseases.
[5] J. Hansen,et al. C1 inhibitor deficiency enhances contact pathway mediated activation of coagulation and venous thrombosis. , 2023, Blood.
[6] X. Solanich,et al. Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Karsdal,et al. The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling , 2022, eBioMedicine.
[8] R. D. De Jongh,et al. Coagulation parameters predict COVID-19-related thrombosis in a neural network with a positive predictive value of 98% , 2022, Frontiers in Immunology.
[9] C. Agrati,et al. SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production , 2022, Cells.
[10] Shaima Hussain Alnajjad,et al. Implications for COVID-19 , 2022, International journal of health sciences.
[11] F. Llopis,et al. Exceptional treatment of COVID-19 pneumonia with icatibant. , 2022, Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias.
[12] J. Bernstein,et al. Inhibition of Prekallikrein for Hereditary Angioedema. , 2022, The New England journal of medicine.
[13] I. De Meester,et al. Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients , 2022, Clinica Chimica Acta.
[14] A. Egesten,et al. Comorbidities in hereditary angioedema—A population‐based cohort study , 2022, Clinical and translational allergy.
[15] B. Stieltjes,et al. Automated lung vessel segmentation reveals blood vessel volume redistribution in viral pneumonia. , 2022, European journal of radiology.
[16] J. Barberà,et al. Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge , 2022, Respiratory Research.
[17] James Batchelor,et al. Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital , 2022, BMJ Open.
[18] S. Nagashima,et al. COVID-19 and Lung Mast Cells: The Kallikrein–Kinin Activation Pathway , 2022, International journal of molecular sciences.
[19] Z. Prohászka,et al. Associations between the von Willebrand Factor—ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality , 2022, Thrombosis and haemostasis.
[20] N. Hacohen,et al. Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19 , 2021, American journal of respiratory and critical care medicine.
[21] K. Preissner,et al. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19 , 2021, Blood Advances.
[22] Dipti K. Pawaskar,et al. A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab , 2021, Clinical and translational science.
[23] M. Netea,et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19 , 2021, Thrombosis Research.
[24] M. Garg,et al. Association of Inflammatory Markers with COVID-19 Outcome among Hospitalized Patients: Experience from a Tertiary Healthcare Center in Western India. , 2021, Maedica.
[25] A. Jannot,et al. Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19 , 2021, TH Open.
[26] T. Molnár,et al. Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19 , 2021, Metabolites.
[27] A. Egli,et al. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study , 2021, Frontiers in Immunology.
[28] M. Guazzi,et al. Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study , 2021, International Journal of Cardiology.
[29] A. Pakhare,et al. Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia , 2021, Cureus.
[30] M. Rava,et al. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? , 2021, Frontiers in Medicine.
[31] Reamer L. Bushardt,et al. Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID‐19: A propensity score‐matched analysis , 2021, Journal of Thrombosis and Haemostasis.
[32] A. V. Sorokina,et al. Pathological Features in 100 Deceased Patients With COVID-19 in Correlation With Clinical and Laboratory Data , 2021, Pathology & Oncology Research.
[33] S. Thiel,et al. Protease inhibitor plasma concentrations associate with COVID-19 infection , 2021, Oxford open immunology.
[34] G. Lippi,et al. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature , 2021, Seminars in Thrombosis and Hemostasis.
[35] M. Landray,et al. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.
[36] Liang Chen,et al. Dynamic changes in coagulation parameters and correlation with disease severity and mortality in patients with COVID-19 , 2021, Aging.
[37] Jiasheng Xu,et al. Dynamic Changes in Coagulation Function in Patients With Pneumonia Under Admission and Non-admission Treatment , 2021, Frontiers in Medicine.
[38] Ramazan Sabırlı,et al. Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study , 2021, Life Sciences.
[39] Safae Abu Yousef,et al. Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study , 2021, Rheumatology International.
[40] L. Bonomo,et al. COVID-19 pneumonia: current evidence of chest imaging features, evolution and prognosis , 2021, Chinese Journal of Academic Radiology.
[41] Brad J. Wood,et al. Remarkable vessel enlargement within lung consolidation in COVID-19 compared to AH1N1 pneumonia: A retrospective study in Italy , 2021, Heliyon.
[42] L. Samavati,et al. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review , 2021, RMD Open.
[43] P. Manunta,et al. Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection , 2021, Journal of Nephrology.
[44] C. Agrati,et al. Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options , 2021, Mediterranean journal of hematology and infectious diseases.
[45] M. Gawaz,et al. Severe SARS-CoV-2 Infection Inhibits Fibrinolysis Leading to Changes in Viscoelastic Properties of Blood Clot: A Descriptive Study of Fibrinolysis in COVID-19 , 2021, Thrombosis and Haemostasis.
[46] B. Nilsson,et al. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System , 2021, Frontiers in Immunology.
[47] C. Fu,et al. The effect of coagulation factors in 2019 novel coronavirus patients , 2021, Medicine.
[48] J. Pedrosa,et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia , 2021, Frontiers in Immunology.
[49] Guangwei Luo,et al. The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression , 2021, The Journal of Immunology.
[50] L. Velloso,et al. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19 , 2021, Viruses.
[51] Achmet Ali,et al. Prognostic Value of Antithrombin Levels in COVID-19 Patients and Impact of Fresh Frozen Plasma Treatment: A Retrospective Study , 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[52] Ying Zhu,et al. Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19 , 2021, BMC Infectious Diseases.
[53] F. Pène,et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality , 2021, Angiogenesis.
[54] J. Haas,et al. Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells , 2021, Circulation.
[55] Ming Chen,et al. Association of coagulation disturbances with severity of COVID-19: a longitudinal study , 2021, Hematology.
[56] Evi X. Stavrou,et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation , 2020, bioRxiv.
[57] G. D'offizi,et al. COVID-19 disease—Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study , 2020, PloS one.
[58] B. Mégarbane,et al. von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients , 2020, British journal of haematology.
[59] N. Mackman,et al. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[60] Xinmin Liu,et al. Coagulopathy in patients with COVID-19: a systematic review and meta-analysis , 2020, Aging.
[61] G. Grasselli,et al. The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.
[62] D. Jiménez,et al. Incidence of venous thromboembolism and bleeding among hospitalized patients with COVID-19: a systematic review and meta-analysis , 2020, Chest.
[63] T. Ortel,et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis , 2020, Journal of thrombosis and haemostasis : JTH.
[64] A. Pesenti,et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity , 2020, Journal of Autoimmunity.
[65] William H. Yang,et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.
[66] M. Serteser,et al. Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients , 2020, PloS one.
[67] N. Barabutis. Unfolded protein response in the COVID-19 context , 2020, Aging and Health Research.
[68] M. Aepfelbacher,et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.
[69] L. V. Van Pelt,et al. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study , 2020, medRxiv.
[70] P. Moceri,et al. High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019 , 2020, Journal of the American Heart Association.
[71] M. Zuin,et al. Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis. , 2020, European Journal of Internal Medicine.
[72] J. Abisheganaden,et al. Temporal changes of haematological and radiological findings of the COVID-19 infection—a review of literature , 2020, BMC Pulmonary Medicine.
[73] P. Saldiva,et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.
[74] M. Fasshauer,et al. Circulating cell adhesion molecules in metabolically healthy obesity , 2020, International Journal of Obesity.
[75] Keith Sigel,et al. An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.
[76] M. Thaysen‐Andersen,et al. Structural and functional diversity of neutrophil glycosylation in innate immunity and related disorders. , 2020, Molecular aspects of medicine.
[77] Stephan Moser,et al. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System , 2020, Frontiers in Immunology.
[78] E. Mylonakis,et al. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis , 2020, Clinical Radiology.
[79] H. Billett,et al. Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA network open.
[80] M. Netea,et al. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19 , 2020, JAMA network open.
[81] C. Gazzaruso,et al. Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity , 2020, Nutrition, Metabolism and Cardiovascular Diseases.
[82] P. D. de Groot,et al. Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. , 2020, Respiratory medicine.
[83] Junyu Lu,et al. Coagulation dysfunction is associated with severity of COVID‐19: A meta‐analysis , 2020, Journal of Medical Virology.
[84] Wen Zeng,et al. Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19 , 2020, Frontiers in Pharmacology.
[85] Liqing Cheng,et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis , 2020, Aging.
[86] B. Mégarbane,et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? , 2020, Thrombosis Research.
[87] Jianfang Liu,et al. Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: A retrospective study , 2020, Clinica Chimica Acta.
[88] S. Tavangar,et al. Pathologic features of COVID-19: A concise review , 2020, Pathology - Research and Practice.
[89] C. D. Dela Cruz,et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.
[90] P. Georgius,et al. COVID-19 as a viral functional ACE2 deficiency disorder with ACE2 related multi-organ disease , 2020, Medical Hypotheses.
[91] E. Messas,et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients , 2020, Angiogenesis.
[92] Fen Li,et al. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross‐sectional study , 2020, Journal of medical virology.
[93] Axel Haverich,et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.
[94] W. Liang,et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China , 2020, Journal of Allergy and Clinical Immunology.
[95] Xiaosheng Wang,et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues , 2020, Infectious Diseases of Poverty.
[96] T. de Giacomo,et al. Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen , 2020, Virchows Archiv.
[97] R. Woods,et al. Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.
[98] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[99] Mario Plebani,et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.
[100] A. Laghi,et al. Chest CT Features of COVID-19 in Rome, Italy , 2020, Radiology.
[101] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[102] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.
[103] D. Sin,et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19 , 2020, European Respiratory Journal.
[104] Tian Huang,et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.
[105] Rui Ji,et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[106] Haibo Xu,et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.
[107] R. Liu,et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.
[108] Nabil Al-Ama,et al. Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications , 2019, The Journal of international medical research.
[109] M. S. Sajib,et al. Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology , 2019, Cells.
[110] William H. Yang,et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.
[111] M. Bader,et al. Kinin B1 receptors as a therapeutic target for inflammation , 2018, Expert opinion on therapeutic targets.
[112] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[113] T. Renné,et al. The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. , 2017, Biochimica et biophysica acta. Molecular cell research.
[114] Chao Lu,et al. Retrospective study , 2016, Medicine.
[115] A. Schmaier,et al. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities , 2016, Journal of thrombosis and haemostasis : JTH.
[116] W. Lumry,et al. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3 , 2015, International Archives of Allergy and Immunology.
[117] T. Mccauley,et al. Pharmacokinetics of single and repeat doses of icatibant , 2015, Clinical pharmacology in drug development.
[118] R. Santos,et al. Angiotensin-(1-7): beyond the cardio-renal actions. , 2013, Clinical science.
[119] A. de la Sierra,et al. Abnormalities of vascular function in resistant hypertension , 2012, Blood pressure.
[120] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[121] W. Lumry,et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[122] T. Ortel,et al. Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.
[123] A. Christensson,et al. Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin12 , 2009, The Journal of Immunology.
[124] Yixue Xue,et al. Bradykinin-induced blood–tumor barrier opening is mediated by tumor necrosis factor-α , 2009, Neuroscience Letters.
[125] Ç. Yenisey,et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation , 2008, Journal of Thrombosis and Thrombolysis.
[126] M. Willingham,et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[127] F. Schmidt. Meta-Analysis , 2008 .
[128] T. Baglin,et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls , 2006, British journal of haematology.
[129] R. D'Agostino,et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. , 2006, Diabetes.
[130] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[131] M. Burns,et al. Case-Control Study , 2020, Definitions.
[132] G. Navis,et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.
[133] J. Manson,et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.
[134] J. Sung,et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.
[135] G. Lip,et al. Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) , 2002, Hypertension.
[136] S. Tanase,et al. Release of a new vascular permeability enhancing peptide from kininogens by human neutrophil elastase. , 2002, Biochemical and biophysical research communications.
[137] H. Arnesen,et al. Increased levels of markers of vascular inflammation in patients with coronary heart disease , 2002, Scandinavian journal of clinical and laboratory investigation.
[138] G. Lip,et al. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. , 2001, American journal of hypertension.
[139] H. Granger,et al. B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF‐2 effects , 1998, British journal of pharmacology.
[140] W. Knaus,et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. , 1997, JAMA.
[141] K. Chung,et al. Bradykinin–evoked sensitization of airway sensory nerves: A mechanism for ACE–inhibitor cough , 1996, Nature Medicine.
[142] D. Ward,et al. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. , 1994, Genomics.
[143] J. Imbs,et al. Cough and ACE inhibitors , 1993, The Lancet.
[144] M. FitzGerald,et al. Captopril and lymphocytic alveolitis. , 1989, BMJ.
[145] K. Siddiqui,et al. Incidence of lupus anticoagulant in hospitalized covid-19 patients. , 2021, American journal of blood research.
[146] Recovery Collaborative Group. Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial , 2020, SSRN Electronic Journal.
[147] Marta Elena Losa-Iglesias,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[148] 藤倉雄二,et al. わが国における成人市中肺炎の原因微生物の変遷(Meta‐analysis and systematic review) , 2017 .
[149] Maja O’Connor. LONGITUDINAL STUDY , 2013 .
[150] V. Preedy,et al. Prospective Cohort Study , 2010 .
[151] T. Zelinka,et al. Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. , 2006, Physiological research.
[152] D. C. Henckel,et al. Case report. , 1995, Journal.
[153] P. Allhoff,et al. The Framingham Offspring Study , 1991 .
[154] M. F. Parry,et al. A Retrospective Analysis , 1990 .
[155] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.